Fundraising Fox

Eli Casdin

Investor

Chief Investment Officer and Founder at Casdin Capital · Board director at C2i Genomics · Board director at Cedilla Therapeutics, Inc. · Board director at Genomatica

New York, New York

Writes $100K – $5M checks · typically $1.5M

About

Eli Casdin authored mid-2000s roadmap The Dawn of Molecular Medicine and backs platforms using biological data as decision-making infrastructure while guiding companies to markets via co‑sponsored CM Life Sciences SPACs.

Contact· self-published, not guessed

Invests in

AgTechBiotechData & InfrastructureFoodTechHealthtechMedical Devices

Board director at C2i Genomics

Intro paths

→

In turn, Eli can intro founders to C2i Genomics's investors below.

C2i Genomics's investors · 5

Casdin CapitalNew York · since 2021iGlobe PartnersSingapore · $600K – $6M checksLionBirdTel Aviv · $200K – $500K checksNFXSan Francisco · $250K – $5M checksSection 32Palo Alto

Co-founders at C2i Genomics

AZ
Asaf ZviranFounder

Board director at Cedilla Therapeutics, Inc.

Intro paths

→

In turn, Eli can intro founders to Cedilla Therapeutics, Inc.'s investors below.

Cedilla Therapeutics, Inc.'s investors · 2

Casdin CapitalNew York · since 2021Third Rock VenturesBoston · $100K – $5M checks · since 2020

Board director at Genomatica

Intro paths

→

In turn, Eli can intro founders to Genomatica's investors below.

Genomatica's investors · 3

Casdin CapitalNew York · since 2021Novo HoldingsCopenhagen · $1.1M – $54M checks · since 2021VantagePoint Capital PartnersSilicon Valley · $2M – $100M checks · since 2021

Co-founders at Genomatica

CSChristophe Schilling
Christophe SchillingCo-founder (former CEO)
BP
Bernhard PalssonCo-founder

Experience

  1. Casdin Capital, LLCChief Investment Officercurrent2011 — presentGreater New York City Area
  2. The Rockefeller UniversityBoard Membercurrent2021 — present
  3. New York Genome CenterBoard Membercurrent2020 — presentNew York, United States
  4. Columbia University School of General StudiesMember, Board of Visitorscurrent2015 — present
  5. Standard BioToolsBoard Membercurrent2022 — present
  6. GeneDxBoard Membercurrent2020 — present
  7. Prominex Inc.Board Membercurrent2018 — presentSan Diego, California
  8. GenomaticaBoard Membercurrent2018 — present
  9. SomaLogicBoard Member2020 — 2024
  10. Tenaya TherapeuticsBoard Member2019 — 2022
  11. EQRxBoard Member2020 — 2022
  12. Exact SciencesBoard Of Directors2017 — 2020Madison, Wisconsin
  13. Relay TherapeuticsBoard Observer2017 — 2019Cambridge, Massachusetts
  14. Magenta TherapeuticsBoard Observer2018 — 2019Cambridge, Massachusetts
  15. Fulcrum TherapeuticsBoard Observer2018 — 2019Cambridge, Ma
  16. InvitaeBoard Observer2013 — 2015
  17. SynapDxBoard Observer2013 — 2015
  18. Alliance BernsteinAnalyst2007 — 2011
  19. Bear StearnsAssociate2007
  20. Cooper Hill PartnersAnalyst2003 — 2006
  21. EDMC ClothingFounder1994 — 2001

Deals · 7

PAIGE.AI, Inc.Board seat

via Casdin Capital · filed Mar 2023 · $39M raise

Cedilla Therapeutics, Inc.Board seat

via Casdin Capital · filed Oct 2021 · $82.6M raise

GenomaticaBoard seat

via Casdin Capital · filed Aug 2021 · $119.1M raise

AbsciBoard seat

via Casdin Capital · filed Mar 2021 · $125M raise

Century Therapeutics, Inc.Board seat

via Casdin Capital · filed Mar 2021 · $160M raise

SomaLogicBoard seat

via Casdin Capital · filed Jan 2021 · $250M raise

Vitruvian NetworksBoard seat

via Casdin Capital · filed Nov 2020 · $75M raise

Attribution from SEC filings, press coverage, and firm rosters.

Other disclosed investments

Board seats

C2i Genomics

Per SEC Form D filings.

Colleagues at Casdin Capital

Alan Huang
Advisor at Casdin Capital
Alex Parker
Advisor at Casdin Capital
Alexandria Fisk
Chief Operating Officer at Casdin Capital
Alley (Welsh) Olshansky
Advisor at Casdin Capital
Angelo Crupi
Chief Compliance Officer at Casdin Capital
Bernie Cooney
Senior Managing Director at Casdin Capital
Brad Weisgerber
Head Trader at Casdin Capital
Carlos Garcia-Echeverria
Advisor at Casdin Capital

Network7

Marc BenioffScout
Co-founder, Chair & CEO of Salesforce
Brook ByersScout
Founder, Kleiner Perkins
Chris GibsonScout
Portfolio Director, Private Equity at Bridges Fund Management Ltd.
Carlo Rizzuto
Managing Director at Versant Ventures
David Schenkein
Investor at GV (Google Ventures)
Jeffrey Bird
Managing Director at Bluebird Ventures
Stephen Knight
President & Senior Managing Partner at F-Prime Capital Partners

Investors connected to Eli in public investor directories — a warm-intro map.

Frequently asked questions

Who is Eli Casdin?
Eli Casdin authored mid-2000s roadmap The Dawn of Molecular Medicine and backs platforms using biological data as decision-making infrastructure while guiding companies to markets via co‑sponsored CM Life Sciences SPACs.
Where does Eli Casdin work?
Eli Casdin is Chief Investment Officer and Founder at Casdin Capital and Board director at C2i Genomics and Board director at Cedilla Therapeutics, Inc. and Board director at Genomatica.
What does Eli Casdin invest in?
Eli Casdin invests in AgTech, Biotech, Data & Infrastructure, FoodTech, Healthtech, Medical Devices.
What check size does Eli Casdin write?
Eli Casdin typically writes checks of $100K – $5M.
What boards does Eli Casdin sit on?
Eli Casdin holds tracked board seats at Absci, C2i Genomics, Cedilla Therapeutics, Inc., Century Therapeutics, Inc., Genomatica, PAIGE.AI, Inc., SomaLogic, Vitruvian Networks.
Where did Eli Casdin go to school?
Eli Casdin studied at Columbia Business School (MBA, Finance - Accounting); Columbia University (Bachelor of Science); University of Vermont.

Same school

Also attended Columbia Business School668

Ryan PetersenFounder & CEO of FlexportAryo TehranianManaging Director at Mayfair Equity PartnersYibo NianInvestment Director at Intel CapitalKesha CashFounder & General Partner at Impact America FundMahati SridharPartner, Rise of the Rest at RevolutionGiuseppe IademarcoHead of Global Partnership at P101 Ventures

+ 662 more

Also attended Columbia University726

Ben HorowitzCo-founder & General Partner at Andreessen HorowitzDoug LeonePartner at Sequoia Capital; former Global Managing PartnerChris DixonFounder & Managing Partner of a16z crypto at Andreessen HorowitzKai-Fu LeeChairman of Sinovation Ventures and CEO of 01.AIGabriella GiglioHR & Executive Talent at General CatalystScott BillerInvestor at GV (Google Ventures)

+ 720 more

Also attended University of Vermont53

Dan BorokCo-Founder and Managing Partner at NVP CapitalArun IyerInvestor at Green FlagMelissa Morano AurigemmaChief of Staff at Exceptional CapitalEvan NisselsonInvestor at LDV CapitalBrian DevaneyPartner at Underscore VCAaron MandellVenture Partner at Prime Movers Lab

+ 47 more

Also attended Riverdale Country School17

Madeleine GoldbergInvestor at Lerer HippeauJonathan MessingOperating Partner at Verissimo VenturesRyan EngelFounder & Managing Partner at Cade VenturesDaniel MaffezzoliPartner at GATHER VENTURESDanny CohenInvestor at RiverPark VenturesWilliam BuehlerInvestor at Camber Partners

+ 11 more

Shared employers

Also worked at GeneDx1

Isaac RoPartner at Catalio Capital Management, LP

Also worked at Relay Therapeutics11

Anneli MathesonExecutive Assistant at Prelude VenturesJulia PianSenior Associate at Atlas VentureDeborah PalestrantPartner, Executive Chair, 4:59 Initiative at 5AM VenturesJakob LovenPartner at Nextech InvestSteve KafkaGeneral Partner at S32Alexis BorisyOperating Chairman at Curie.Bio

+ 5 more

Also worked at Magenta Therapeutics3

Carol SuhPartner at ARCH Venture PartnersChristina IsacsonPartner at Lightstone VenturesDima VremenkoFounder at Inkbox

Also worked at Fulcrum Therapeutics2

Walter KowtoniukInvestor at Third Rock VenturesRyan PeerAssociate at Frazier Life Sciences